Free tool
FAERS Monitor: Claritin-D 24 Hour
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020470 or its brand name (Claritin-D 24 Hour, Loratadine, Pseudoephedrine Sulfate). Reports on generic versions are filed under their own applications.
Reports
6,977
Serious
1,257
18% of reports
Hospitalization
497
Death reported
72
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,537
- insomnia677
- drug effect decreased395
- product use issue381
- dizziness324
- somnolence259
- headache252
- nausea231
- fatigue219
- dyspnoea203
- feeling abnormal193
- palpitations186
- off label use178
- dry mouth176
- anxiety158
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 114 |
| 2005 | 114 |
| 2006 | 95 |
| 2007 | 84 |
| 2008 | 81 |
| 2009 | 107 |
| 2010 | 106 |
| 2011 | 127 |
| 2012 | 325 |
| 2013 | 417 |
| 2014 | 1,591 |
| 2015 | 702 |
| 2016 | 738 |
| 2017 | 601 |
| 2018 | 330 |
| 2019 | 307 |
| 2020 | 244 |
| 2021 | 81 |
| 2022 | 206 |
| 2023 | 301 |
| 2024 | 109 |
| 2025 | 121 |
| 2026 | 76 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,182 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug effect decreasedSignal | 395 | 22.3 | 20.2 | 7,962 |
| insomniaSignal | 677 | 7.7 | 7.1 | 3,967 |
| dry mouthSignal | 176 | 6.6 | 5.7 | 824 |
| product use issueSignal | 381 | 6.1 | 5.6 | 1,639 |
| palpitationsSignal | 186 | 4.8 | 4.2 | 557 |
| somnolenceSignal | 259 | 3.9 | 3.4 | 556 |
| drug ineffectiveSignal | 1,537 | 3.5 | 3.4 | 2,950 |
| feeling abnormalSignal | 193 | 2.4 | 2.1 | 163 |
| dizziness | 324 | 2.0 | 1.8 | 155 |
| anxiety | 158 | 1.7 | 1.4 | 43 |
| headache | 252 | 1.2 | 1.1 | 9 |
| dyspnoea | 203 | 1.1 | 0.9 | 1 |
| nausea | 231 | 0.9 | 0.8 | 4 |
| fatigue | 219 | 0.8 | 0.7 | 6 |
| off label use | 178 | 0.6 | 0.5 | 45 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.